All News

    Cost-Benefits, Efficacy of Biosimilar Ranibizumab vs Aflibercept for nAMD in Japan

    January 22nd 2025

    By Skylar Jeremias

    Article

    When compared with reference aflibercept, a biosimilar ranibizumab was a clinically effective and cost-saving alternative in a study assessing Japanese patients with different subtypes of neovascular age-related macular degeneration (nAMD).

    A Banner Year for Biosimilars: The 19 FDA Approvals From 2024

    January 21st 2025

    By Skylar Jeremias

    Article

    In 2024, the FDA approved 19 biosimilars across various therapeutic areas, including the first biosimilars for ustekinumab and denosumab, marking significant progress in expanding treatment options and market competition.

    BioRationality: Biosimilar Associations and Stakeholders Representing Biosimilars

    January 20th 2025

    By Skylar Jeremias

    Article

    Sarfaraz K. Niazi, PhD, dives into the role that biosimilar associations and organizations play in promoting biosimilars as well as how their stakeholder demographic and main objectives differ from one another.

    FTC Releases Second Report on PBMs Meddling in Generic Drug Markets

    January 19th 2025

    By Skylar Jeremias

    Article

    The 3 largest pharmacy benefit managers (PBMs) increased many specialty generic drugs prices by hundreds of percent, with some drugs seeing thousands of percent markups, according to the Federal Trade Commission (FTC)’s second interim report on PBM practices.

    Functional Similarity Between Ustekinumab Biosimilar ABP 654, Stelara in Crohn Disease

    January 18th 2025

    By Deana Ferreri, PhD

    Article

    Functional similarity of the ustekinumab biosimilar ABP 654 (Wezlana) and the reference product (Stelara) was confirmed by a series of in vitro studies, which support the totality of evidence for the biosimliar's FDA approval.

    The Top 5 Biosimilar Articles for the Week of January 13

    January 17th 2025

    By Cameron Santoro

    Video

    Here are the top 5 biosimilar articles for the week of January 13, 2025.

    Biosimilars Drive Cost Savings and Achieve 53% Market Share Across Treatment Areas

    January 16th 2025

    By Skylar Jeremias

    Article

    Biosimilar launches achieve a 53% market share and a 53% reduction in average drug costs after 5 years of biosimilar competition, according to Samsung Bioepis’ most recent market report, showcasing notable pricing trends and market share disparities across therapeutic areas.

    Biosimilar Tocilizumab Cost-Effective for Treatment of Rheumatoid Arthritis in Spain

    January 16th 2025

    By Cameron Santoro

    Article

    A study from Spain found a subcutaneous tocilizumab biosimilar to be cost-effective when treating patients with rheumatoid arthritis (RA) after experiencing improved outcomes.

    Improving Biosimilar Access Through Global Regulatory Convergence

    January 15th 2025

    By Skylar Jeremias

    Article

    Achieving global regulatory harmonization for biosimilar vaccines and immunotherapies is essential to improving market access, reducing costs, and enhancing patient outcomes by streamlining approval processes, fostering international collaboration, and addressing regulatory disparities.

    Cost-Efficiency in Action: Denmark's Transition to Biosimilar Adalimumab

    January 14th 2025

    By Skylar Jeremias

    Article

    The nationwide mandatory switch from Humira (reference adalimumab) to biosimilar adalimumab in Denmark led to no increase in total health care costs over 9 months, with significant cost reductions for those who switched to GP2017 specifically, highlighting the economic feasibility of biosimilar adoption.